Objectives/Hypothesis: Clinical staging of early head and neck squamous cell carcinoma (SCCHN) is often inaccurate, leading to elective neck dissection to detect the 30% of patients with micrometastatic disease. Sentinel node biopsy accurately stages the regional lymphatics, but intraoperative pathology is only moderately sensitive, and final pathology takes several days to complete. To facilitate immediate neck dissection where necessary, we have identified several promising marker genes of SCCHN metastasis and developed a rapid, accurate, and automated quantitative real-time polymerase chain reaction (PCR) (qRT-PCR) assay for intraoperative use.
INTRODUCTION
Metastasis to cervical lymph nodes (LNs) occurs in approximately 30% of patients with early squamous cell carcinoma of the head and neck (SCCHN) and is associated with regional recurrence and poor outcome. 1, 2 Physical examination, imaging, and histopathologic characteristics of the primary tumor are not accurate enough to determine TNM stage and to guide treatment reliably. Although close observation (i.e., watchful waiting) and elective neck irradiation remain options, most clinicians favor excision of the regional lymphatics at the time of resection of the primary cancer for accurate staging. However, 60% to 70% of the patients who undergo surgery ultimately do not have nodal disease pathologically (pN0) and therefore are theoretically overtreated (Fig. 1 ). More accurate, targeted, and lessinvasive approaches would prevent elective neck dissection (END) in many of the patients without metastatic disease.
Sentinel node biopsy (SNB) allows the surgeon to identify and excise targeted ''first echelon'' LNs that reliably drain the site of a primary malignancy. 3, 4 This technique offers a less-invasive means of staging lymphatic basins in patients with an identified primary cancer and permits detailed histologic, immunohistochemical (IHC), and molecular examination of clinically occult micrometastases. The use of this technique might better direct the application of END in cN0 SCCHN patients, thereby reducing treatment-associated morbidity, which may even occur in a selective neck dissection (SND). 5 The sequelae of SND include adhesive capsulitis of the shoulder, lower lip paresis, and changes in the contour of the neck. Recent studies have documented negligible morbidity or functional deficits with SNB, as compared with SND. 6 A large, multi-institutional pathologic validation trial has supported previous single-institution studies, establishing that the sentinel node concept applies to SCCHN, [7] [8] [9] [10] [11] [12] [13] [14] as well as to cutaneous melanoma and breast cancer. The recently published American College of Surgeons Oncology Group (ACOSOG) prospective multicenter trial of 168 patients demonstrated that the pathologic status of the sentinel lymph node (SLN) correlated highly with the results of subsequent, immediate formal lymphadenectomy, yielding a negative predictive value (NPV) of 96% for accurately staging a pN0 neck using SNB. 15 A continuing major limitation of SNB is the need for a reliable method of intraoperative detection of metastasis, so that a neck dissection could be performed at the same time, when necessary. This would avoid a second surgery, with its associated costs, treatment delay, and the potential for complications. However, intraoperative frozen section and imprint cytology have insufficient sensitivity and reproducibility, 8 suggesting a need for intraoperative tools to permit accurate decisionmaking as to need for END ( Fig. 1 ). In addition, step sectioning and IHC, which are performed only on SLNs, typically add 1 to 2 days and may identify additional micrometastases. 15 A molecular technique, which can sample a larger portion of the SLNs and amplify microscopic tumor deposits, has the potential for greater accuracy and the rapidity necessary for intraoperative decision making. 16, 17 To this end, we have systematically investigated the identification of reliable tumor marker genes, expressed selectively in tumor-positive nodes using quantitative reverse-transcriptase polymerase chain reaction (PCR) (qRT-PCR) and have developed a rapid, multiplexed qRT-PCR assay to provide immediate information regarding the status of the SLN; we have validated it for clinical application. Here we describe the identification and selection of the two most promising markers from a large screen of more than 40 tumor-associated genes from a training set of SCCHN primary and metastatic tumors. These tumor markers, pemphigus vulgaris antigen (PVA) and tumor-associated calcium signal transducer 1 (TACSTD1), were then validated in a test set of cervical LNs (of which 62 of 442 were tumor positive), comparing qRT-PCR with standard hematoxylinand-eosin (H&E) and IHC analysis. After this validation was performed, the multiplexed, rapid (35 minutes) qRT-PCR assay was performed using a subset of 102 nodes, of which 40 were tumor positive, to mimic the clinical picture of occult metastasis to cervical LN observed in early SCCHN. Our rapid, highly accurate qRT-PCR technique may facilitate more routine application of minimally invasive techniques to stage the neck, such as SNB, and direct more appropriate use of neck dissection in SCCHN patients. Such a technique could be extended to the posttreatment setting for detection of residual disease and to guide salvage therapy.
MATERIALS AND METHODS

Patients and LN Collection
After approval from the institutional review board was received, written informed consent was obtained from all patients donating specimens for this study. Primary tumors and histologically tumor-free or tumor-involved nodes were harvested at surgery and immediately snap-frozen at À80 C until RNA extraction was done. Of these specimens, eight sets of paired human head and neck primary tumors and tumor-containing metastatic LNs (from the same 8 patients with SCCHN) were included in the initial tumor gene marker study. 16 Benign LNs (n ¼ 21) were obtained from patients undergoing surgery for nonmalignant esophageal disorders. All cervical LNs were collected from patients undergoing neck dissections for HNSCC, with various primary sites including the oral cavity, oropharynx, larynx, and hypopharynx. A validation set of 442 LNs from 92 patients were separately harvested and sliced in alternating 1-mm sections, with half of the sections used for pathologic diagnosis and the other half used for this study. To reduce discrepancies between the two halves, the research halves were embedded in optimal cutting temperature (OCT, Torrance, CA) compound, and one section was mounted on a slide, H&E Fig. 1 . Current algorithm for intraoperative diagnosis of sentinel lymph node (SLN) status in head and neck squamous cell carcinoma. Low sensitivity of intraoperative frozen section or touch prep leads to the need for 12 of 30 patients with micrometastasis to undergo repeat surgery (completion neck dissection) after final pathologic review of the sentinel node biopsy. A rapid intraoperative, accurate test for metastasis would potentially reduce the need for a second procedure and serve as an adjunct to pathologic review for intraoperative decision making. Pos ¼ positive; Neg ¼ negative. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] stained, and read by a head and neck pathologist. The OCTembedded nodes were stored at À80 C before processing and RNA isolation.
Tissues and Pathologic Evaluation
Archived tissues from all patients in this study were reviewed by two individuals who specialize in head and neck pathology (R.R.S. or S.C.), who were blinded as to the original diagnosis, which was reconfirmed histologically. Twenty 5-lm sections were cut from each OCT compound-embedded tissue for RNA isolation. In addition, sections were cut and placed on slides for H&E and IHC analysis at the beginning, middle (between the 10th and 11th sections for RNA), and end of the sections for RNA isolation (Fig. 2 ). All three H&E slides from each specimen underwent pathologic review to confirm presence and percentage of tumor and to identify the presence of any contaminating tissues. All of the unstained slides were stored at À20 . IHC evaluation was done using the antibody pan keratin (AE1/AE3) mixture (DAKO, Carpinteria, CA) and Vector Elite ABC kit and Vector AEC Chromagen (Vector Laboratories, Burlingame, CA). IHC was used as needed to confirm the H&E histology.
Histologic analysis was performed for each LN, consisting of an H&E-stained frozen section of alternating pieces for research, to be cut at a later date for both RNA isolation and histologic review by two pathologists, and consensus was reached using both H&E and IHC (''research pathology''); finally, alternate pieces of each node were fixed and embedded, and H&E-stained sections were reviewed and entered into the medical record (permanent, or ''final'' pathology). Finally, nodes were classified as negative, positive, isolated tumor cells (ITCs), or, if tissues were considered inadequate, nondiagnostic. From these data, each node was also given an ''overall pathology'' call based on all three evaluations, in which any positive result trumped ITC, and any ITC trumped negative results.
Screening Approach
Identification of potential tumor markers. An extensive literature and public database survey was conducted to identify any potential markers. Resources for this survey included PubMed, OMIM, UniGene (http://www.ncbi.nlm.nih. gov/), GeneCards (http://bioinfo.weizmann.ac.il/cards), and Cancer Genome Anatomy Project (http://cgap.nci.nih.gov). Our survey goal was to identify genes with moderate to high expression in SCCHN and low expression in normal LNs. In addition, genes reported to be upregulated in SCCHN and genes with restricted tissue distribution were considered potentially useful. Finally, genes reported to be cancer specific, such as the cancer testis antigens and telomerase reverse transcriptase (hTERT), were evaluated.
The screening was conducted in two phases. All potential markers entered the primary screening phase, and expression was analyzed in six primary tumors and 10 benign LNs obtained from patients without cancer (5 RNA pools with 2 LN RNAs per pool). Markers that showed good characteristics for LN metastasis detection (consistent, high expression in tumors and very low expression in benign nodes) passed into the secondary screening phase. The secondary screen consisted of expression analysis of 26 primary tumors, 19 histologically positive LNs, and 21 benign LNs without cancer.
Validation cohort of LNs. After the secondary marker screen, an independent cohort of 442 nodes from 92 different SCCHN patients was prospectively collected. This validation set was characterized pathologically using the same approach as in the primary and secondary screens for correlation with molecular results. Within this validation cohort, a set of 103 nodes (43 tumor positive, 41.7%) was used to validate the rapid, multiplexed assay, which amplified two tumor marker genes, PVA and TACSTD1, and an internal control gene, b-glucuronidase (GUSB). 18 Quantitative PCR quantification with SYBR Green. All quantitative PCR for marker screening was done on the ABI Prism 7700 Sequence Detection Instrument (Applied Biosystems, Foster City, CA). Relative expression of the marker genes was calculated using the DCT (CT ¼ cycle time) methods previously described 16 and with GUSB as the endogenous control gene. All assays were designed for use with 5 0 nuclease hybridization probes, although the primary screening was done using SYBR Green (Molecular Probes, Eugene, OR) quantification to save cost. Assays were designed using the ABI Primer Express Version 2.0 software (Foster City, CA) and, where possible, amplicons spanned exon junctions to provide cDNA specificity. All primer pairs were tested for amplification specificity (generation of a single band on gels) at 60 C, 62 C, and 64 C annealing temperature. In addition, PCR efficiency was estimated using SYBR Green quantification before use in the primary screen. Further optimization and more precise estimates of efficiency were done with 5 0 nuclease probes for all assays used in the secondary screen. A mixture of the Universal Human Reference RNA (Stratagene, La Jolla, CA) and RNAs from human placenta, thyroid, heart, colon, PCI-13 cell line, and the SKBR3 cell line served as a universal positive expression control for all the genes in the marker screening process. For SYBR Green I-based quantitative PCR, each 50-lL reaction contained 1Â TaqMan buffer A (Applied Biosystems), 300 nmol/ L each deoxynucleotide triphosphate, 3.5 mmol/L MgCl2, 0.06 U/lL Amplitaq Gold (Applied Biosystems), 0.25Â SYBR Green I, and 200 nmol/L each primer. The amplification program consisted of two stages with an initial 95 C Taq activation stage for 12 minutes followed by 40 cycles of 95 C denaturation for 15 seconds, 60 C, 62 C, or 64 C anneal/extend for 60 seconds, and a 10-second data collection step at a temperature 2 C to 4 C below the melting temperature of the specific PCR product being amplified. After amplification, a melting curve analysis was done by collecting fluorescence data while increasing the temperature from 60 C to 95 C in 20 minutes.
Tissue processing for RNA isolation and research pathology review. Five-micron serial sections were cut from each OCT-embedded LN half, with the initial and final tissue sections mounted on slides for histologic analysis with H&E staining (Fig. 2 ). The next adjacent tissue section was mounted on slides and stained with pancytokeratin IHC for histopathology. IHC evaluation was done using the antibody pan keratin (AE1/AE3) mixture (DAKO) and Vector Elite ABC kit and Vector AEC Chromagen (Vector Laboratories). The intervening sections were distributed 4:1:4:1:4, and so on, such that four sections were immediately placed in chaotropic lysis buffer for RNA isolation (total of 50-60 sections), and every fifth section was mounted on a slide for histologic review (every five sections are considered a level) ( Fig. 2 ). All unstained slides from levels 2 to 9 were fixed in acetone and stored at À20 C. All H&E and IHC slides from levels 1 and 10 of the LNs were reviewed by two specialized head and neck pathologists to confirm the presence and percentage of tumor and to identify the presence of contaminating tissues, as were slides from the GeneXpert (Cepheid, Sunnyvale, CA) validation set.
RNA isolation and cDNA synthesis. RNA was isolated using the Stratagene RNA isolation minikit (Stratagene) using the manufacturer's described protocol. Reverse transcription was done in 100-lL reaction volumes with random hexamer priming and SuperScript II (Invitrogen) reverse transcriptase as per our previous studies. 16 All screening quantitative PCR was performed on the Stratagene MX300P cycler. Relative expression of the marker genes (PVA and TACSTD1) was calculated using the DCT methods as previously described 16 and with GUSB as the endogenous control gene. TACSTD1 is also known as epithelial cell adhesion molecule (EpCAM). Primer and probe sequences for each gene were as published previously. 16 GeneXpert multiplex assay development. Multiplex qRT-PCR assays can suffer from limited linear dynamic range due to common reagent utilization. The SmartCycler (Cepheid) and the GeneXpert both employ a method called temperaturecontrolled primer limiting to inhibit the assay that reaches threshold first in order to decrease competition between the simultaneous assays. The PVA, TACSTD1, GUSB (triplex) assay used in this study is very similar to our previously published GeneXpert assay for breast cancer. 19 Duplex and then triplex assays were first developed on the SmartCycler (2-to 3-hour machine) before transitioning to the GeneXpert (35-minute machine). Briefly, PCR efficiency and dynamic range were assessed for duplex assays (TACSTD1/GUS and PVA/GUSB) using serial dilutions of cDNA with high expression of the respective target genes (normal esophagus RNA for PVA, normal colon RNA for TACSTD1) in a background of total spleen cDNA. Linear dynamic range for the triplex assay was then tested to ensure that all three assays functioned well in the ranges needed for LN classification. At this point, the triplex quantitative PCR assay was incorporated into the GeneXpert system to facilitate automated RNA isolation, reverse transcription, and quantitative PCR. Reproducibility of the quantification of each marker gene was then tested on the GeneXpert using serial dilutions of total RNA known to have high expression of PVA and TACSTD1. RNAs were diluted in a background of lysate from LNs negative for disease to mimic a true test scenario. Six serial dilutions were performed, and each assay was repeated four times on the GeneXpert to assess reproducibility across a range of target gene expression. Primer and probe sequences used in the GeneXpert for each gene have been previously published. 16 GENEXPERT ANALYSIS. Twenty-four 5-lm sections of OCTembedded tissue were sectioned into 800 lL of GeneXpert lysis buffer (Cepheid). The lysis buffer was filtered through a 0.22-lm syringe filter (Osmonics Inc., Westborough, MA) and loaded into a GeneXpert cartridge. The automated processes of RNA isolation, reverse transcription, and qRT-PCR on the GeneXpert are described elsewhere. Briefly, the filtered tissue lysate was placed into a reservoir on the GeneXpert cartridge ( Supplementary Figures 2 and 3) , and all necessary reagents for RNA isolation, reverse transcription, and quantitative PCR were placed in additional reservoirs. The cartridge was placed in the GeneXpert, and the remaining steps were fully automated. The tissue lysate is first passed over an RNA isolation resin and washed, and then RNA is eluted into a clean reservoir. Reverse-transcription reagents are added and the mixture is pumped into the integrated PCR tube and heated for cDNA synthesis. The cDNA is then removed from the PCR tube, and PCR reagents (primers, probes, etc.) are added. The mixture is returned to the PCR tube and thermal cycling is done (overall total time, %35 minutes). Probe fluorescence is monitored at each cycle, and results are updated on the monitor in real time. For this study, the rapid PCR assay consisted of a multiplex qRT-PCR for PVA, TACSTD1, and the endogenous control gene, GUSB.
Analysis of LNs using the GeneXpert. One hundred and three (n ¼ 102) LNs were analyzed on the GeneXpert. Frozen tissue pieces, which were recut for RNA and tissue sections, were evaluated blindly by two fellowship-trained head and neck pathologists (GeneXpert research pathology). Twenty-four 5-lM sections of OCT-embedded tissue were sectioned into 800 lL of GeneXpert lysis buffer for each node, with two initial and final tissue sections mounted on slides for H&E and IHC histopathology. The lysate was then filtered through a 0.22-lm syringe filter and loaded into a GeneXpert cartridge. The exact details of the RNA isolation, reverse transcription, and qRT-PCR on the automated GeneXpert system are described. 16 Statistical analysis. In the primary screen, data from the melting curve were analyzed using the ABI Prism 7700 Dissociation Curve Analysis 1.0 software. The first derivative of the melting curve was used to determine the product Tm as well as to establish the presence of the specific product in each sample. In general, samples were analyzed in duplicate PCR reactions, and the average cycle time (CT) value was used in the expression analysis. However, in the secondary screen, triplicate runs were done for each individual benign node, and the lowest CT value was used in the calculation of relative expression to obtain the highest value of background expression for the sample.
GENERATION OF PREDICTION RULES. After the primary marker screen, six markers that passed the secondary screen were evaluated individually and in combination with other markers. The characteristics used to evaluate markers were sensitivity, specificity, classification, accuracy, and the area under the receiver operating characteristic (ROC) curve. For individual markers, a cutoff value was determined that maximized the classification accuracy (proportion of LNs correctly classified). In cases wherein classification accuracy was 100%, the cutoff was set at the midpoint between the highest expressing negative node and the lowest expressing positive node. Markers were also combined into pairs for LN classification, and a linear prediction rule was generated for each pair. The rule was equivalent to the linear predictor that equalized the fitted probabilities above and below the linear boundary. That is, points on the boundary line had a predicted probability midway between the numeric scores assigned to positive and negative nodes. For example, if positive nodes were assigned a score of 2 and benign nodes a score of 1, predicted scores >1.5 were classified as positive.
INTERNAL VALIDATION OF PREDICTION RULES. Internal validation of prediction rules was conducted by nonparametric bootstrap resampling using Efron and Tibshirani's improved bootstrap method, 16 in which 500 bootstrap samples of LNs are selected from the pool of all positive and negative nodes. The optimism in the original estimates of sensitivity, specificity, and classification accuracy are then calculated as the difference between the bootstrap classification statistic applied to the original data and applied to the bootstrap data. The average difference over all bootstrap samples is computed and reported as the bias in the values derived from the observed data and then subtracted from the original estimates to produce the bootstrap-validated estimates.
DIAGNOSTIC ACCURACY OF STANDARD qRT-PCR AND THE
GENEXPERT ASSAYS. The reference standard was established as follows: 1) for research pathology, it was a consensus of two academic pathologists applying frozen H&E and IHC. To explore the diagnostic potential of individual markers with both standard qRT-PCR and the GeneXpert, ROC curves were constructed, and the cutoff value of each marker that produced the highest overall classification accuracy was selected. The diagnostic parameters of sensitivity, specificity, positive predictive value, NPV, and overall accuracy were calculated for each cutoff. In addition, the area under the ROC curve was estimated. For the purpose of developing a diagnostic model and identifying which marker or combination of markers was most important, a different strategy was used. In this approach, the sample of 442 LNs were collected from 92 patients and therefore were not considered to be independently distributed. For this reason, we applied a generalized linear model with random effects. This model used a logit link to estimate the binomial variable, positive or negative by pathology, as a function of marker RNA expression level, controlling for the random effect of patient. 20 The best fitting model was selected based on the likelihood ratio test and the number of model parameters (Akaike's information criteria 21 ) . A GeneXpert classification model was developed with conventional (fixed effects) logistic regression. The model was used to predict the probability that that a node was positive, and the range of predicted probabilities served as a list of potential cutoff values in an ROC analysis. In addition to logistic regression models, recursive portioning and nearest neighbor models were fit, but neither 
RESULTS
Primary Screening for Suitable Tumor Markers of Nodal Metastatic Disease
Our literature and database surveys identified 40 genes overexpressed by aerodigestive tract malignancies for evaluation in the primary tumor marker screen. 16, 22 All of these genes were analyzed for expression in six primary SCCHN and 10 benign LNs using qRT-PCR. Resulting data for the 11 genes with the highest median expression in tumors, and well-described biologic function in SCCHN, are shown in Table I . In addition, we calculated the ratio of relative expression between the lowest expressing tumor and the highest expressing benign node and between the median expression in tumors and the highest expressing benign node. Some genes had no detectable expression in benign nodes, and therefore ratios could not be calculated.
Using three parameters (median expression in the tumors, lowest tumor/highest benign node, and median tumor/highest benign node ratios), two genes were selected with expression characteristics most suitable for detection of SCCHN LN metastases. These genes, PVA and TACSTD1, had median tumor/highest benign node ratios >500 (Table I) and therefore had the potential to detect small foci of tumor, while still discriminating negative nodes. In addition, all genes except cytokeratin (CK)19 also had lowest tumor/highest benign node ratios >100, indicating that they were expressed at reasonably high levels in all six tumors tested in the primary screen. Melanoma-associated antigen (MAGE)-A3 22 and CK7 were omitted from the secondary screen because of a combination of low median tumor/highest benign node expression ratios and relatively low median expression in tumors. Similarly, CK18 was excluded based on a combination of a low expression ratio in primary tumors. EGFR was included in the secondary screen based on its frequent use as a prognostic and therapeutic marker in SCCHN, 23 but its differential expression between tumorpositive and benign nodes was not sufficiently promising (data not shown).
Secondary Tumor Marker Screen Using the Best Six Tumor Markers Identified in the Primary Screen
For the secondary marker screen, histologic evaluation of 26 primary tumor specimens was then performed *Five hundred bootstrap samples of lymph node expression levels were generated, and a new decision rule based on the most accurate cutoff was formulated each time (total of 500 decision rules). The optimism for each bootstrap sample is calculated as the difference between the classification statistics applied to the original data and applied to the bootstrap data. The average over all bootstrap samples is computed and reported as the bias in the values derived from the observed data (Efron's enhanced bootstrap prediction error estimate). † Bias is the enhanced bootstrap estimate of optimism or the amount that classification accuracy is overestimated when tested on the original data.
for the best markers, specifically focused on PVA and TACSTD1. Similarly, we studied 19 histologically positive nodes, in which the median tumor percentage was 70% (range, 2% to 90%). Eight patients' paired primary tumors and metastatic nodes were included. The relative expression profiles of the 11 markers selected for the secondary screen are shown in Table I . The data show that all markers are expressed in positive LNs as well as in primary tumors, indicating that metastatic tumor cells continue to express these genes. Figure 3A indicates that relative expression cutoff values can be established (dotted line) to provide the most accurate classification of histologically positive and benign nodes. These cutoff values were used to calculate classification characteristics (sensitivity, specificity, area under the ROC curve, and overall classification accuracy) for each marker, as well as using a standard time-frame (3-to 4-hour) multiplex assay with simultaneous amplification of both markers. These results are presented in Figure 3B and Table II .
Pathologic Analysis of Nodal Disease
As an independent validation set, 442 LNs from 92 patients (demographic data provided in Table III) were analyzed through research frozen section (H&E plus IHC) and final pathology of fixed sections. Overall (combined) results classified 380 nodes as negative (2 nodes were diagnosed as positive for ITC and treated as pN0) and 62 nodes as tumor positive ( Figure 3B ). Comparison of two separate, blinded pathologists' reviews with the overall pathology result (excluding ITCs, which were treated as benign) indicated that concordance was >99% in all cases. However, some discrepancy in sensitivity between research pathology and permanent pathology was observed (86.9% and 91.8% respectively). The difference between research and permanent pathology results with overall (consensus) pathology was presumably due to sampling error of slightly different sections of the nodes, which were processed as shown in Figure 2 . We focused on research pathology because these sections were closer (adjacent) to those used for RNA extraction and PCR.
Validation of qRT-PCR Markers and Correlation With Histologic Detection of Metastasis
After selection of PVA and TACSTD1 as the most promising gene markers from the secondary screen, the 442 cervical LN validation set was analyzed by qRT-PCR for these markers, and molecular results were compared to research pathology (Tables IV-VII) (Fig. 3B) . In general, qRT-PCR results were slightly more concordant with research pathology than with overall pathology (mean accuracy, 96% vs. 94%), probably reflecting the increased sampling error inherent in the comparison with overall consensus pathology. Individually, all markers demonstrated high overall accuracy compared with both pathology endpoints, but PVA clearly provided superior sensitivity (92% vs. research pathology, see Tables IV and V) and hence superior NPV. ROC curve analysis also identified PVA as the best marker, although the area-under-the-curve confidence intervals for PVA and TACSTD1 overlapped. Paired combinations of markers were also evaluated (Tables II, IV-VII) with TACSTD1 and PVA, providing the best correlation with pathology. 
Automated GeneXpert Rapid Assay Development and Reproducibility Assessment
For application of a rapid qRT-PCR assay suitable for use within an intraoperative time frame, a triplex assay was developed for PVA, TACSTD1, and control gene, GUSB. PCR efficiencies for multiplex assays ranged from 96.3% to 98.8% (Fig. 4) , and the triplex assay showed good linearity in the range needed to discriminate positive from negative nodes. Replicate experiments on the GeneXpert resulted in an intraclass correlation coefficient of 0.90 for PVA and 0.97 for TACSTD1. The coefficient of variation was 18.2% for PVA and 3.9% for TACSTD1.
GeneXpert Rapid Analysis of Model LN Cohort
A total of 102 LNs were evaluated using the triplex assay on the GeneXpert. Results were compared to concomitant research pathology (examination of frozen sections taken adjacent to the tissue used for the rapid, multiplex qRT-PCR) and consensus pathology (a consensus based on all histologic analyses performed on the node). Of the 102 nodes, 40 (39.2%) were tumor positive by consensus pathology, and 62 were tumor negative. These results are shown in Figure 5 . Sampling slightly different nodal sections in the setting of micrometastatic deposits led to discrepancy in seven nodes from research pathology to consensus results. Using the rapid, multiplex assay, NPV compared with research pathology, the most accurate comparison of adjacent tissue sections analyzed pathologically, was 95.5% (Tables IV and V) .
For each LN section tested in this validation set using the rapid assay, TACSTD1 and PVA expression data from the triplex GeneXpert assay were converted to a probability of being positive using a logistic regression model to conform to the clinical scenario in which approximately 30% of nodes are tumor positive, instead of 39.2% (40 of 102) by final consensus pathology or 35% by research pathology in this data set. We used 35% because research pathology more accurately conformed to the section tested after RNA isolation. Using this approach, the overall accuracy of qRT-PCR compared with research pathology was 94.2% and compared with consensus pathology was 90.3%. The sensitivity and specificity compared with research pathology were 91.7% and 95.5%, respectively, and compared with consensus pathology were 86% and 93.3%. Tenfold cross validation indicated that these accuracy levels are likely to be quite robust, as the estimated accuracy only dropped by 4% to 5%.
DISCUSSION
To facilitate selection of pNþ SNB patients who require END, we have developed a completely automated, multiplex qRT-PCR assay that can accurately detect LN metastasis in SCCHN. This assay can be performed in approximately 35 minutes and thus could be performed intraoperatively, in conjunction with frozen section to detect metastasis, even in those with 3% to 5% nodal involvement. This study is the first of its kind in SCCHN to adapt the use of a rapid automated qRT-PCR assay that can be used in an intraoperative setting to detect LN metastasis.
Because many patients with SCCHN routinely undergo END, the ability to accurately and rapidly stage the cN0 neck has great clinical application, to avoid morbidity of open neck dissection. SLN biopsy is a promising, minimally invasive technique that has recently been validated to accurately stage the neck in early SCCHN, 15 with an NPV of 96%. However, widespread clinical application of SNB is severely hampered by the lack of an intraoperative method that is rapid and accurate to detect metastatic disease.
To accomplish this goal, an extensive tumor gene marker screen was used, in which two distinct mRNA markers were identified and then validated in both single and multiplex assays using a large independent set of more than 440 grossly tumor-negative LNs. Furthermore, after validation of these novel markers, we adapted the qRT-PCR assay to a rapid time frame and applied the triplex assay (2 tumor marker genes and 1 control gene) to a subset of 102 LNs (of which 40 nodes were tumor positive) to demonstrate the accuracy and clinical applicability of this approach.
Although intraoperative frozen section has been evaluated for SNB, its sensitivity is not very high (%60% 8 ), and an inherent problem with intraoperative frozen section is sampling error, because even one or two 5-lm frozen sections of a 1-mm LN only corresponds to 0.1%, which is visually analyzed and therefore may miss metastasis. This is particularly true if the metastatic deposit is located near the capsule, as opposed to the midportion of the node most likely to be bilobed into two sections. Frozen-section histology is also subject to technical difficulties in sample and section preparation, including interpretive challenges, all of which are heavily dependent on the skill and experience of the pathologist and support staff. Thus, even final assessment of step-sectioned formalin-fixed, paraffin embedded sections, which samples a larger percentage of the node and is the gold standard, may not find micrometastatic deposits (<2 mm and >0.2 mm), not to mention ITCs (tumor clusters <0.2 mm), as suggested by the fact that 7% to 10% of pN0 patients after END experience recurrent disease in the neck. 24, 25 Hence, a method of evaluating a large portion of SLN for metastasis that is both rapid and accurate would be of great benefit.
Others have tried to predict nodal metastasis using gene-expression profiles from a primary tumor biopsy. 26, 27 However, no reliable gene prediction profile has been developed to use the primary tumor mRNA profile in classifying presence of disease in cN0 patients. Thus, direct analysis of the draining SLN is necessary, a procedure which has been recently validated in a large, prospective, multicenter trial. 15 The GeneXpert assay has several advantages over previous methods of molecular diagnosis, as well as conventional pathologic analysis, in detecting occult metastasis in SLNs of SCCHN. First of all, this is the first instrument that can do a fully automated RNA isolation and qRT-PCR in less than 35 minutes, which could easily fit into an intraoperative time frame. Closure of the primary tumor defect and/or neck incisions could be undertaken after SLN removal and during pathologic and qRT-PCR analysis. Second, the objective nature of the assay eliminates the uncertainty and discordance rates with frozen-section pathology analysis, a clearly documented issue. 8 Finally, with further work, this wet assay can become automated into a dry assay, which will remove any doubt of potential human error with the sample processing (i.e., pipetting error). Further development of the PVA assay, such as was done for TACSTD1 in breast cancer, 19 should lead to higher PCR efficiency. Thus, we anticipate technical improvement as greater developmental effort is devoted to preparing rapid PVA amplification for clinical evaluation.
Our results show that the GeneXpert assay had a very high NPV (>96%); however, three tumor-positive nodes were ultimately ''missed'' (they were below the qRT-PCR threshold). Histologic analysis of these three nodes showed <5% tumor, which was absent on later sections that were likely placed in RNA lysis buffer and analyzed by qRT-PCR. The fact that PVA and TACSTD1 did not reveal high expression in both cases could be an artifact of the tissue-sectioning protocol. Moreover, the GeneXpert could detect <3% tumor in an LN that two pathologists missed on H&E analysis, showing that the qRT-PCR assay reliably detects micrometastatic disease. Furthermore, optimization of these marker assays, such as inclusion of a larger number of alternating sections for PCR versus frozen-section analysis, will be used to avoid sampling errors in micrometastatic disease.
Although other LN qRT-PCR studies report homogenizing whole portions of or even complete LNs for RNA isolation, we believe that LNs can be processed in such a way to permit both qRT-PCR and routine pathologic evaluation in parallel on immediately adjacent tissue sections. In this way, we anticipate that the GeneXpert assay may be used in the common clinical scenario in which the pathologist suspects metastatic disease in the frozen section but cannot confirm the diagnosis solely based on H&E analysis. Instead of running the risk of having the patient potentially return for surgery in the case that IHC staining picks up metastatic disease, one can run the GeneXpert assay in less than 35 minutes intraoperatively, which can indicate, with more than 95% accuracy, that the SLN is free of tumor. The high NPV is of greatest clinical importance, 15 because it saves those patients free of disease from having a longer procedure (END) and inpatient hospital stay. The nodal analyses could be performed during an intraoperative sequence in which the primary tumor and/or neck incisions are being closed, with a high likelihood (70%) that no further surgery will be needed.
We and others have previously shown that RT-PCR can potentially be more sensitive than routine pathology for analysis of LNs. 19, 28 In SCCHN specifically, studies on molecular analysis of cervical LN metastasis have used a variety of techniques, including PCR amplification to detect p53 mutations, 29 IHC staining (with or without serial sectioning) and histopathologic examination, 8 and slower, standard RT-PCR-based analysis of tumor marker gene expression. 30 Nieuwenhuis et al. showed the prognostic value of qRT-PCR in pN0 SCCHN patients. 28 This same group also showed the potential for molecular staging of cervical nodes by using tissue obtained via fine-needle aspiration. 31 Our technique could be readily adapted to this clinical scenario, in the setting of clinical or radiographic suspicion.
Our comprehensive marker screen to identify the best mRNA markers for detection of LN metastases in SCCHN can also provide biologic insights as to mechanisms of metastasis. This marker screen has identified two (PVA and TACSTD1) extremely robust, tumorrelated markers, any one of which might be used in a single-marker assay. PVA, also known as desmoglein 3 (DSG-3), is a 130-kDa surface glycoprotein that is the serologic target in the autoimmune skin disease pemphigus vulgaris. PVA is a member of the desmoglein subfamily of the desmosomal cadherins, and the gene encoding this protein has been mapped to the long arm of chromosome 18 and is known to contain 15 exons. TACSTD1, also known as EPCAM, is a human cell surface antigen that has been used in studies to detect LN micrometastases in a variety of tumor types, including SCCHN. 32 To our knowledge, we were the first to identify PVA in detecting LN metastases in SCCHN. 16 This rapid, multiplex assay was incorporated into a completely automated RNA isolation and qRT-PCR instrument (the GeneXpert) for molecular diagnostic testing and is currently in use for bioterrorism applications. The GeneXpert is an automated cartridge processor with integrated real-time PCR capability (Supplementary Figure 2 ). Each single-use GeneXpert cartridge consists of multiple reagent reservoirs, a syringe barrel, and a valve mechanism that allows transfer of reagents between reservoirs. In addition, the cartridges used in this study have a solid-phase matrix for nucleic acid purification and isolation. Finally, each cartridge has a PCR tube that can be accessed from specific reagent reservoirs to allow loading of reaction components into the PCR tube for quantitative and/or RT-PCR. The GeneXpert instrument itself interfaces with the cartridge to control reagent movement and also houses heat plates and optical excite/detect blocks to facilitate real-time PCR. The details of RNA isolation and qRT-PCR using the GeneXpert have been published elsewhere. 19 It is hoped that biotechnology companies will develop these and other instruments to facilitate further development of this field.
In conclusion, we have demonstrated that qRT-PCR can detect, with high sensitivity and specificity, metastatic disease in LNs of patients with SCCHN. In addition, we have shown the feasibility of automated, intraoperative staging of cervical LNs and the possibility that such an approach may eventually prove superior to conventional pathology. Staging of the cN0 neck is currently a topic of intense interest in the head and neck oncologic community, with the goal that therapeutic surgical and adjuvant treatment be administered to those most likely to benefit from it. Whereas the ACOSOG Z0360 trial effectively validated the multiple single-institution studies, supporting SNB for staging the cN0 neck in SCCHN, it is unlikely that SNB will be widely accepted without a rapid, accurate, and standardized method of staging the SLNs. Our development of such an assay and identification of discriminatory marker genes provides crucial data necessary for the incorporation of qRT-PCR into future clinical studies applying SLN mapping to clinical practice for patients with this disease. Separate studies evaluating its use in the posttreatment setting may be warranted. Further efforts, such as the conversion to a dry assay on the GeneXpert system, as well as the implementation of this technology into a multicenter SLN trial, are underway.
